De-Novo Belatacept Therapy is Associated with an Increased Risk of Invasive CMV Disease After Kidney Transplantation.

被引：0
|
作者：
Petrossian, G. [1 ]
Ortiz, J. [2 ]
Addonizio, K. [1 ]
Hsiao, A. [1 ]
Teixeira, L. [1 ]
Koizumi, N. [3 ]
James, R. [3 ]
Patel, S. [4 ]
Conti, D. [2 ]
Plews, R. [2 ]
机构：
[1] Albany Med Ctr, Albany, NY USA
[2] Albany Med Ctr, Div Renal & Pancreat Transplant Serv, Albany, NY USA
[3] George Mason Univ, Fairfax, VA 22030 USA
[4] UMC Las Vegas, Las Vegas, NV USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2022年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
413
引用
收藏
页码：512 / 512
页数：1
相关论文
共 50 条
  • [31] Impact of Everolimus Added to a De Novo Belatacept Regimen on the Risk of BK Viremia After Kidney Transplant
    Larsen, C.
    Alseiari, M.
    Chandran, S.
    Vincenti, F.
    Wojciechowski, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 482 - 483
  • [32] De-novo inflammatory bowel disease is a significant risk factor for primary sclerosing cholangitis recurrence after liver transplantation
    Bajer, L.
    Sticova, E.
    Macinga, P.
    Janousek, R.
    Trunecka, P.
    Spicak, J.
    Drastich, P.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S461 - S462
  • [33] De-Novo anti-HLA Antibodies After Renal Transplantation: Prevalance and Risk Factors
    Suvak, Burak
    Keven, Kenan
    Sengul, Sule
    Kurultak, Ilhan
    Tuzuner, Acar
    Hazinedaroglu, Selcuk
    Tutkak, Huseyin
    TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL, 2011, 20 (01): : 77 - 82
  • [34] Everolimus and mTORC1 Signaling in Energy Balance after De Novo Kidney Transplantation.
    Junge, G.
    Wang, Z.
    Schwende, H.
    Cornu-Artis, C.
    Witte, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 317 - 317
  • [35] Renal allograft survival in the de novo hemolytic uremic syndrome (HUS) after kidney transplantation.
    Raez, L
    Santos, E
    Angulo, J
    Restrepo, A
    Bymes, J
    BLOOD, 1998, 92 (10) : 35A - 35A
  • [36] Factors Associated with the Development of Chronic Kidney Disease after Liver Transplantation.
    Kalisvaart, M.
    Schlegel, A.
    Trivedi, P.
    Roberts, K.
    Mirza, D.
    Perera, T.
    Isaac, J.
    Ferguson, J.
    Muiesan, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 305 - 306
  • [37] The Evolving Use of Higher Risk Grafts Is Associated With an Increased Incidence of Acute Kidney Injury after Liver Transplantation.
    Leithead, Joanna A.
    Rajoriya, Neil
    Gunson, Bridget K.
    Muiesan, Paolo
    Ferguson, James W.
    LIVER TRANSPLANTATION, 2014, 20 : S145 - S145
  • [38] A Case Series of De Novo Inflammatory Bowel Disease After Kidney Transplantation
    Azevedo, P.
    Freitas, C.
    Aguiar, P.
    Silva, H.
    Santos, T.
    Farrajota, P.
    Almeida, M.
    Pedroso, S.
    Martins, L. S.
    Dias, L.
    Vizcaino, R.
    Castro Henriques, A.
    Cabrita, A.
    TRANSPLANTATION PROCEEDINGS, 2013, 45 (03) : 1084 - 1087
  • [39] Role of Immune-Senescence in the development of de-novo Donor-Specific Antibodies after Kidney Transplantation
    von Moos, Seraina
    Schalk, Gesa
    Laube, Guido F.
    Mueller, Thomas
    SWISS MEDICAL WEEKLY, 2017, 147 : 24S - 24S
  • [40] Incidence and risk factors for de-novo NAFLD after liver transplantation: real-world data
    Guetzlaff, Lea
    Campos-Murguia, Alejandro
    Bosselmann, Emily
    Baumann, Anna Katharina
    Hartleben, Bjoern
    Jaeckel, Elmar
    Taubert, Richard
    Hupa-Breier, Katharina Luise
    JOURNAL OF HEPATOLOGY, 2023, 78 : S466 - S466
12345